Literature DB >> 15726512

Combined modality treatment for rectal cancer.

Andrew X Zhu1, Christopher G Willett.   

Abstract

Significant gains have been achieved in the integration of radiation therapy (RT) and chemotherapy with surgery in the management of patients with localized rectal cancer. Treatment combinations of RT and chemotherapy with surgery have evolved to neoadjuvant approaches of these modalities to enhance sphincter preservation, tumor control, and reduction of acute and late treatment-related morbidity. Although 5-fluorouracil (5-FU)-based chemotherapy in combination with RT remains the standard adjuvant therapy for rectal cancer, the integration of novel chemotherapeutic agents and biologic modulators is being actively investigated.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15726512     DOI: 10.1053/j.seminoncol.2004.09.032

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  2 in total

1.  Perfusion CT in solid body-tumours. Part II: Clinical applications and future development.

Authors:  M Bellomi; S Viotti; L Preda; G D'Andrea; L Bonello; G Petralia
Journal:  Radiol Med       Date:  2010-03-09       Impact factor: 3.469

2.  Predictive clinicopathologic factors for limited response of T3 rectal cancer to combined modality therapy.

Authors:  Anne Y Lin; W Douglas Wong; Jinru Shia; Bruce D Minsky; Larissa K Temple; José G Guillem; Philip B Paty; Martin R Weiser
Journal:  Int J Colorectal Dis       Date:  2007-11-29       Impact factor: 2.571

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.